Cargando…
IMMU-12. PHASE I/II TRIAL OF IMMUNOTHERAPY WITH FUSIONS OF DENDRITIC CELLS AND TUMOR CELLS FOR RELAPSED OR REFRACTORY BRAIN TUMORS IN CHILDREN AND YOUNG ADULTS
BACKGROUND/OBJECTIVES: Relapsed or refractory brain tumors in childhood continue to have a dismal prognosis in spite of intensive multidisciplinary treatment. Cancer immunotherapy is newly developed to be expected as next promising treatment for highly aggressive pediatric cancer. This trial was des...
Autores principales: | Yamaoka, Masayoshi, Akasaki, Yasuharu, Takei, Jun, Akiyama, Masaharu, Tasaki, Tetsunori, Ohashi, Toya, Ida, Hiroyuki, Yanagisawa, Takaaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715224/ http://dx.doi.org/10.1093/neuonc/noaa222.368 |
Ejemplares similares
-
PEDT-03 A clinical trial of dendritic cell-based immunotherapy for refractory brain tumors in children
por: Akasaki, Yasuharu, et al.
Publicado: (2020) -
IMMU-17. Comprehensive immunological gene expression profiling of pediatric brain tumors
por: Levine, Adrian, et al.
Publicado: (2022) -
IMMU-01. IMMUNE CHECKPOINT INHIBITION FOR PEDIATRIC CNS TUMORS: A SINGLE INSTITUTION EXPERIENCE
por: Cacciotti, Chantel, et al.
Publicado: (2020) -
IMMU-15. PROTEOGENOMIC DISCOVERY OF NOVEL TUMOR PEPTIDES AS NEOANTIGENS FOR PERSONALIZED T CELL IMMUNOTHERAPY IN MEDULLOBLASTOMA
por: Rivero-Hinojosa, Samuel, et al.
Publicado: (2020) -
IMMU-10. TUMOR ASSOCIATED MYELOID CELLS DRIVE THE IMMUNOBIOLOGY OF HIGH RISK PEDIATRIC EPENDYMOMA
por: Griesinger, Andrea, et al.
Publicado: (2022)